Biotech entity
pharma is the sole category represented across all 4 tracked stories. Of the tracked stories, 4 of 4 also mention China, the most common co-covered peer. That works out to roughly 2.2 stories per week across a 13-day span. The busiest single day carried 2.
Last mentioned: Mar 7, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 4 tracked stories. Of the tracked stories, 4 of 4 also mention China, the most common co-covered peer. That works out to roughly 2.2 stories per week across a 13-day span. The busiest single day carried 2. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. The 8 average consequence score is above the beat benchmark of 6.1 in the same window. This profile follows 4 Biotech stories mentioning National Medical Products Administration (NMPA) across the period from March 7, 2026 to March 19, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 188 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering National Medical Products Administration (NMPA). Shared-story counts are live from our verified record — not editorial picks.
Healthy China 2030 Deadline
Target date for achieving major healthcare and biotech self-sufficiency milestones.
Strategic Target
Deadline for China to become the primary global exporter of medical technology standards.
Annual Progress Review
First assessment of the 15th Five-Year Plan's initial biotech milestones.
R&D Tax Incentive Launch
Specialized tax breaks for high-tech biotech firms are rolled out nationwide.
NMPA Reform Implementation
New guidelines for accelerated clinical trial approvals take effect.
Official Launch
President Xi Jinping unveils the 15th FYP at the National People's Congress.
15th FYP Announcement
China officially prioritizes tech self-reliance as the central pillar of the 2026-2030 plan.
Policy Framework Unveiled
China details the 2026 policy mix focusing on innovation and global sharing.
Leadership Mandate
New policy shift explicitly targets global leadership over 'catching up' with Western tech.
Implementation Phase
Expected rollout of specific subsidies and domestic-first procurement policies.
15th FYP Drafting
Central Committee reviews the initial draft of the 2026-2030 strategic plan.
Patent Milestone
China surpasses the US in total international patent filings for CRISPR and AI-drug discovery.
Geopolitical Escalation
U.S. introduces Biosecure Act, targeting major Chinese biotech entities.
14th Five-Year Plan
China emphasizes 'self-reliance' and domestic technology loops.
14th Five-Year Plan
Initial focus on 'Dual Circulation' and building basic biotech infrastructure.
14th FYP Implementation
Focus on 'Dual Circulation' and initial biotech innovation pivot.
President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.
China’s latest strategic roadmap shifts from a 'catch-up' posture to a mandate for global leadership in frontier technologies. This pivot places biotechnology and genomic medicine at the center of national security and economic growth, challenging decades of U.S. dominance in drug innovation.
China has officially signaled a shift toward total technological self-reliance in its 15th Five-Year Plan, prioritizing the domestic life sciences and pharmaceutical sectors. This strategic pivot aims to insulate China’s healthcare infrastructure from global supply chain volatility and geopolitical pressures while fostering a homegrown innovation ecosystem.
China has detailed a comprehensive 2026 policy framework aimed at accelerating domestic biotech innovation while expanding international market access. The initiative prioritizes 'new quality productive forces' in drug development and streamlines regulatory pathways for global pharmaceutical collaborations.
National Medical Products Administration (NMPA) is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
